NM-2201
NM-2201 is a synthetic cannabinoid that has been identified in herbal blends. Its name refers to the company that first synthesized it, NIMH. It is part of the indole class of cannabinoids.
Chemistry[edit | edit source]
NM-2201 is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is closely related to other indole-based synthetic cannabinoids like AM-2201 and 5F-PB-22.
Effects[edit | edit source]
The effects of NM-2201 are not well-studied. However, it is known to be a potent agonist of the CB1 receptor, which is the same receptor that THC, the primary psychoactive component of cannabis, binds to. This suggests that NM-2201 may have similar psychoactive effects to THC, although this has not been confirmed in scientific studies.
Legal Status[edit | edit source]
The legal status of NM-2201 varies by country. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug. In Canada, it is a Schedule II drug. In Japan, it is a controlled substance.
See Also[edit | edit source]
References[edit | edit source]
NM-2201 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD